Microbiology 3- Hospital Acquired Infection and immunity Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Describe Prontosil: the first example of a sulphonamide antibiotic

A

Bacteriostatic.
Synthetic
Examples include sulpha-methoxazole. Sometimes used together with Trimethoprim (co-trimoxazole).
Used to treat UTIs, RTIs, bacteraemia and prophylaxis for HIV+ individuals.
Becoming more common due to resistance to other antimicrobials, despite some host toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe beta-lactams

A

Interfere with the synthesis of the peptidoglycan component of the bacterial cell wall.
Examples include Penicillin and methicillin.
Bind to penicillin-binding proteins.
PBPs catalyse a number of steps in the synthesis of peptidoglycan.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What type of bacteria is prontosil effective against

A

Gram-negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the development of antibiotics and its importance

A

Prior to the discovery of prontosil & penicillin even minor infections were potentially fatal. Surgery was a major risk.
The potential of prontosil took years to be realised and was never patented to treat infection.
Penicillin was discovered by chance by Sir Alexander Fleming at St. Mary’s Hospital.
However, Fleming realised that an irritating contaminant actually held the key to defeating bacterial infections.
Chain, Florey and Heatly contributed to developing ways to mass produce and administer penicillin.
Fleming, Chain & Florey won the 1945 Nobel prize in Medicine or Physiology.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is an antibiotic

A

An antibiotic is an antimicrobial agent produced by a microorganism that kills or inhibits other microorganisms.
Most antibiotics in use today are produced by soil-dwelling fungi (Penicillium and Cephalosporium) or bacteria (Streptomyces and Bacillus).
However, antibiotics commonly used today encompass a range of natural, semi-synthetic and synthetic chemicals with antimicrobial activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is meant by antimicrobial

A

Antimicrobial – chemical that selectively kills or inhibits microbes (bacteria, fungi, viruses).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is meant by bactericidal

A

Kills bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is meant by bacteriostatic

A

Stops bacteria growing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is meant by anti-septic

A

chemical that kills or inhibits microbes that is usually used topically to prevent infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why has the development of antibiotics slowed

A

After 1950s no economic incentive to develop more antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is meant by the minimal inhibitory concentration

A

Minimal inhibitory concentration (MIC) = the lowest concentration of AB required to inhibit growth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe antibiotic resistance

A

Low MIC- SENSITIVE
High MIC- RESISTANT
Breakpoint conc is clinically achievable concentration, hence bacteria with MIC higher than breakpoint are resistant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Explain how resistance may exist before the antibiotic was used

A

Some strains may be resistant. Some isolates of S. aureus were resistant to penicillin from the start!
Routine use of penicillin provided selective pressure for the acquisition and maintenance of resistance genes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe antibiotic by natural selection

A

Population contains cells with AB resitance due to mutations/acquired DNA – possibly with a fitness cost e.g. Slow growth
In absence of selection pressure (e.g. ABs) AB resistant strains have no advantage (and may have a disadvantage)
Low prevalence of AB resistant strains in patient population
In presence of selection pressure (e.g. Abs) resistant mutants outcompete WT
High prevalence of AB resistant strains in patient population

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the misconceptions at the dawn of the antibiotic era

A
Resistance against more than one class of antibiotics at the same time would not occur.
Horizontal gene transfer would not occur.
Resistant organisms would be significantly less ‘fit’ (sometimes true, sometimes not).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the different mechanisms of bacterial genetic variability

A

Point mutations may occur in a nucleotide base pair, which is referred to as microevolutionary change. These mutations may alter the target site of an antimicrobial agent, interfering with its activity.
Macroevolutionary change results in rearrangement of large segments of DNA as a single event. These rearrangements may include inversions, duplications, insertions, deletions or transposition of large sequences of DNA from location of bacterial chromosome to another.
Acquisition of foreign DNA carried by plasmids, bacteriophages or transposable genetic elements. These foreign elements give the organism the ability to adapt to antimicrobial activity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the economic costs of antibiotic resistance bacteria

A

Less effective antibiotics results in increased morbidity, mortality, length of hospital stay and subsequent cost. Requires more antibiotics, which increases the chance for more resistance.
Increased time to effective therapy.
Requirement for additional approaches – e.g. surgery.
Use of expensive therapy (newer drugs).
Use of more toxic drugs e.g. vancomycin.
Use of less effective ‘second choice’ antibiotics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Why do pharma companies not want to develop antibiotics

A

Less financial incentive, less profits in developing drugs that only certain people can use.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When does resistance usually emerge

A

Resistance usually emerges soon after the arrival of a new AB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

List the major gram-negative bacteria that are multi-drug AB resistant

A
Pseudomonas aeruginosa
Cystic fibrosis, burn wound infections. Survives on abiotic surfaces.
E. Coli (ESBL)
GI infect., neonatal meningitis, septicaemia, UTI.
E. coli, Klebsiella spp (NDM-1) 
As above.
Salmonella spp. (MDR)
GI infect. , typhoid fever.
Acinetobacter baumannii (MDRAB)
Opportunistic, wounds, UTI, pneumonia (VAP). Survives on abiotic surfaces.
Neisseria gonorrhoeae
Gonorrhoea.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

List the major gram-positive bacteria that are multi-drug AB resistant

A

Staphylococcus aureus (MRSA, VISA)
Wound and skin infect. pneumonia, septicaemia, infective endocarditis.
Streptococcus pneumoniae
Pneumonia, septicaemia.
Clostridium difficle
Pseudomembranous colitis, antibiotic-associated diarrhoea.
Enterococcus spp (VRE)
UTI, bacteraemia, infective endocarditis.

Mycobacterium tuberculosis (MDRTB, XDRTB)
Tuberculosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Describe aminoglycosides

A

E.g. Gentamicin, streptomycin.
Bactericidal.
Target protein synthesis (30S ribosomaml subunit), RNA proofreading and cause damage to cell membrane.
Toxicity has limited use, but resistance to other antibiotics has led to increasing use.
In general, aminoglycosides kill aerobic gram-negative enteric organisms (enteric organisms are the bugs that call the G.I tract their home). Most end in -mycin
Aminoglycosides are among the handful drugs that kill Pseudomonas aeruginosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Why are aminoglycosides often used with penicillin.

A

Aminoglycosides must diffuse across the cell wall to enter the bacterial cell, so they are often used with penicillin, which breaks down this wall to facilitate diffusion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

List the side effects of aminoglycosides

A

Eighth cranial nerve toxicity: vertigo, hearing loss
Renal toxicity- removed by Kidney, follow patient BUN and creatine levels which increase with kidney damage
Neuromuscular blockade- unable to move muscle or breathe
Side effects occur if dose is high, the drug level I the blood is checked after steady state levels have been achieved.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe rifampicin

A

Bactericidal.
Targets RpoB subunit of RNA polymerase.
Spontaneous resistance is frequent.
Makes secretions go orange/red – affects compliance.
Inhibits DNA-dependent-RNA polymerase of the mycobacterium tuberculosis bugs.

26
Q

List the side effects of rifampicin

A

Hepatitis
Induces the P450 enzyme system. This results in decreased half life of certain drugs in patients such as oral contraceptives.

27
Q

Describe vancomycin

A

Bactericidal.
Targets Lipid II component of cell wall biosynthesis, as well as wall crosslinking via D-ala residues which inhibits transpeptidation, preventing the formation of the peptidoglycan cell wall
Toxicity has limited use, but resistance to other antibiotics has led to increasing use e.g. against MRSA
Covers all gram-positive bacteria.

28
Q

How is it an advantage that vancomycin in not absorbed orally

A

In the treatment of C.Difficile related infections, vancomycin cruises down the GI tract unabsorbed, and kills the C.Difficile.

29
Q

What usually follows the rapid infusion of vancomycin

A

Redness- due to the nonimmunologic release of histamines.

30
Q

Describe linezolid

A

Bacteriostatic.
Inhibits the initiation of protein synthesis by binding to the 50S rRNA subunit.
Gram-positive spectrum of activity- including those resistant to other microbials.

31
Q

List the side effects of linezolid

A

Serotonin syndrome if used with antidepressants

Thrombocytopenia, anaemia and neutropenia

32
Q

Describe daptomycin

A
Bactericidal.
Targets bacterial cell membrane, altering its electrical charge and transport.
Gram-positive spectrum of activity.
Toxicity limits dose.
Active against MRSA
Associated with myopathy.
33
Q

Describe the action of antibiotics

A

Antibiotics target many different bacterial processes and are selectively toxic

34
Q

Describe selective toxicity

A

The large number of differences between mammals and bacteria result in multiple targets for antibiotic therapy – selective toxicity

35
Q

What is the danger of pseudomonas in hospitals

A

They can replicate on medical equipment such as ventilators.

36
Q

State the 4 distinct mechanisms of antibiotic resistance

A

Altered target site.
Inactivation of antibiotic.
Altered metabolism.
Decreased drug accumulation.

37
Q

Explain how an altered target site can lead to antibiotic resistance

A

Can arise via acquisition of alternative gene or a gene that encodes a target-modifying enzyme.
Methicillin-resistant Staphylococcus aureus (MRSA) encodes an alternative PBP (PBP2a) with low affinity for beta-lactams.
Streptococcus pneumoniae resistance to erythromycin occurs via the acquisition of the erm gene, which encodes an enzyme that methylates the AB target site in the 50S ribosomal subunit.- failure of the antibiotic to bind to ribosomes disrupts its ability to inhibit protein synthesis and cell growth.
Alterations of cell wall precursor targets- glycopeptide antibiotics bind with lower affinity.

38
Q

Describe how inactivation of the antibiotic can lead to antibiotic resistance

A

Enzymatic degradation or alteration, rendering antibiotic ineffective.
Examples include beta-lactamase (bla) and chloramphenicol acetyl-transferase (cat).
ESBL and NDM-1 are examples of broad-spectrum beta-lactamases (can degrade a wide range of beta-lactams, including newest).
ESBLS= extended spectrum beta lactamases
New Delhi metallo-beta-lactamase 1.
Inactivation can also be enzyme-independent (membrane phospholipids).
Beta-lactam ring is split

39
Q

Describe how altered metabolism of the antibiotic can lead to antibiotic resistance

A

Increased production of enzyme substrate can out-compete antibiotic inhibitor (e.g. increased production of PABA confers resistance to sulfonamides).
Alternatively, bacteria switch to other metabolic pathways, reducing requirement for PABA.

40
Q

Describe how decreased drug accumulation can lead to antibiotic resistance

A

Reduced penetration of AB into bacterial cell (permeability) and/or increased efflux of AB out of the cell – drug does not reach concentration required to be effective.
Mutations resulting in the loss of specific porins can occur and may lead to increased resistance to hydrophilic antibiotics, such as penicillin.

41
Q

Can multiple resistance mechanisms co-exist

A

Yes- N. gonorrhoea

42
Q

List some examples of resistance mechanisms against certain antibiotics

A

Penicillin Penicillinases Plasmid-transformation
Penicillin Target site modification Point mutation
Tetracycline Efflux pump Plasmid-conjugation
Quinolone Target site modification Point mutation
Cefotaxime Target site modification Point mutation
Spectinomycin Target site modification Point mutation

43
Q

Can we just increase the dose to overcome resistance

A

No- we need to change the drug

44
Q

Describe another mechanism of antibiotic resistance

A

Bacteria can break themselves up to act as a decoy- soak up the antibiotics.

45
Q

Describe macrolides

A

E.g. Erythromycin, azithromycin.
Gram-positive and some Gram-negative infections.
Targets 50S ribosomal subunit preventing amino-acyl transfer and thus truncation of polypeptides.

46
Q

Describe quinolones

A

Synthetic, broad spectrum, bactericidal.

Target DNA gyrase in Gm-ve and topoisomerase IV in Gm+ve.

47
Q

Describe the sources of antibiotic resistance genes

A

Plasmids – extra-chromosomal circular DNA, often multiple copy. Often carry mutliple AB res genes – selection for one maintains resistance to all.
Transposons. Integrate into chromosomal DNA. Allow transfer of genes from plasmid to chromosome and vice versa.
Naked DNA. DNA from dead bacteria released into environment.

48
Q

Describe the mechanisms through which AB resistance genes can be shared between bacteria

A

Transformation (uptake of extracellular DNA)
Conjugation (pilus-mediated DNA transfer)
Transduction (phage-mediated DNA transfer)

49
Q

Describe how antibiotic resistance is not a new trait of bacteria

A

Resistance determinants for tetracycline, b-lactams and vancomycin found in microbial samples that are 30,000 years old!

Antibiotics are natural products, secreted by one organism to kill another – competitive advantage.

Natural selection has been driving antibiotic production and the development of resistance mechanisms for millions of years.

Human use of antibiotics has provided strong selective pressure for the acquisition or development of antibiotic resistance genes.

Some opportunistic pathogens (e.g. A. baumannii, S. maltophila) are very resistant to antibiotics despite little exposure to antimicrobial therapy.

50
Q

Describe the non-genetic mechanism of drug resistance/ treatment failure

A
Biofilm
Intracellular location- can hide inside cells- hard to get antibiotic in
Slow growth
Spores
Persisters
51
Q

Describe some other reasons for treatment failure

A

Inappropriate choice for organism
Poor penetration of AB into target site
Inappropriate dose (half life)
Inappropriate administration (oral vs IV)
Presence of AB resistance within commensal flora e.g. secretion of beta-lactamase

52
Q

Explain how we can measure resistance

A

Very important to consider that measurements made in vitro may not fully reflect the situation in vivo!
Swabs are typically streaked out onto diagnostic agar to identify causative organism.
Once identified, the pathogen streaked over a plate and then over-laid with AB-containing test strips or discs.
Other approaches include broth micro-dilution and PCR detection of resistance genes.

53
Q

Explain how hospitals provide a strong selection pressure for AB resistance

A

Large numbers of infected people receiving high doses of antibiotics - strong selective pressure for emergence/maintenance of AB resistance
Presence of pathogens, staff vectors, open wounds, injected medical devices (IV catheters), disruption of normal flora due to antibiotic/prophylactic therapy- why rate of hospital acquired infections is high.

54
Q

List some hospital acquired infections

A
Methicillin-resistant S. aureus (MRSA)
Vancomycin-insensitive S. aureus (VISA)
Clostridium difficle
Vancomycin-resistant enterococci (VRE)
E. coli (ESBL/NDM-1) 
P. aeruginosa
Acineterbacter baumannii
Stenotrophomonas maltophilia
55
Q

List some risk factors for hospital acquired infections

A

High number of ill people! (immunosuppression)
Crowded wards
Presence of pathogens
Broken skin – surgical wound/IV catheter
Indwelling devices - intubation
AB therapy may suppress normal flora
Transmission by staff – contact with multiple patients

56
Q

Describe how AB therapy can impair commensal flora

A

In health, commensal organisms can out-compete pathogen WRT adhesion, metabolism, growth. Pathogen cannot colonise at levels sufficient for infection.

57
Q

How can we address resistance to reduce the severity of bacterial and nosocomial infections

A

Prescribing strategies – tighter controls, temporary withdrawal of certain classes. Restriction of ABs for certain serious infections
Reduce use of broad-spectrum antibiotics
Quicker identification of infections caused by resistant strains
Combination therapy
Knowledge of local strains/resistance patterns
Use the narrowest spectrum antibiotic possible
Infection control measures also work

58
Q

Describe how we can overcome resistance

A

Modification of existing medications to e.g. Prevent cleavage (beta-lactams) or enhance efficacy. E.g. Methicillin.
Combinations of antibiotic + inhibitor of e.g. Beta-lactamase. E.g. Augmentin.

However, this is a reactive approach in response to emergence of resistance!

59
Q

What may the future of antibiotics hold

A

New antibiotics
New vaccines
Better screening and decolonisation
Novel approaches – phage lysins, photo-active compounds, siRNA, Quorum Sensing inhibitors
Anti-infectives – MAb or peptide blocking
Use of non-pathogenic competitor strains

60
Q

What is the problem with combination therapy

A

Some antibiotics are antagonistic-work against each other, poor results in RCTs.

61
Q

Describe the situation with antibiotics

A

Resistance has been reported in all major antibiotics.